Paper Details

  1. Home
  2. Paper Details

Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

Author: BellN H, ChesnutC H, DelmasP D, EnsrudK E, GenantH K, HarrisS T, McClungM R, SingerF R, StockJ L, YoodR A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Alendronate significantly increases BMD at the lumbar spine, hip, and total body, and is well tolerated at therapeutic doses (5 or 10 mg daily) in the treatment of osteoporosis in postmenopausal women.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The effects of the aminobisphosphonate alendronate sodium on bone mass and markers of bone remodeling were investigated. PATIENTS AND METHODS: In a multicenter, randomized, double-blind, placebo-controlled, 2-year study, 188 postmenopausal women, aged 42 to 75 years, with low bone miner...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0002-9343(99)80134-x

データ提供：米国国立医学図書館（NLM）

Alendronate: A Powerful Oasis in the Desert of Osteoporosis

Osteoporosis, a debilitating bone disease, can feel like a desert of bone fragility, leaving sufferers vulnerable to fractures. This research, like a beacon of hope, investigates the potential of alendronate, a bisphosphonate medication, in treating postmenopausal osteoporosis.

The study, conducted in a multicenter, randomized, double-blind, placebo-controlled trial, examines the effects of alendronate on bone mass and bone remodeling markers in postmenopausal women with low bone mineral density. The findings reveal a significant increase in bone mass and a reduction in bone resorption markers in patients receiving alendronate, offering a promising therapeutic approach for osteoporosis.

Strengthening Bones in the Desert of Fragility

The study demonstrates that alendronate is an effective treatment for postmenopausal osteoporosis, significantly increasing bone mass and reducing bone resorption markers compared to placebo. These findings highlight the potential of alendronate in preventing fractures and improving bone health in individuals with osteoporosis.

Navigating the Desert of Bone Health

This research emphasizes the importance of early intervention and treatment for osteoporosis. It suggests that alendronate, in conjunction with calcium supplementation, can provide a much-needed oasis for individuals battling bone fragility, reducing the risk of fractures and improving overall bone health.

Dr. Camel's Conclusion

This study offers a compelling exploration of the effectiveness of alendronate in treating postmenopausal osteoporosis, providing a valuable resource for individuals seeking to strengthen their bones and reduce the risk of fractures. It underscores the importance of proactive bone health management, particularly for postmenopausal women.

Date :
  1. Date Completed 1995-08-31
  2. Date Revised 2019-06-27
Further Info :

Pubmed ID

7625419

DOI: Digital Object Identifier

10.1016/s0002-9343(99)80134-x

Related Literature

Article Analysis
・Effects of alendronate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.